ERNA

Ernexa TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$0.32

-96.0% vs current

Most likely

Base case

45%

Probability

Target price

$0.14

-98.3% vs current

B-

Bear case

30%

Probability

Target price

$0.05

-99.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-01

AI commentary

Primary-source tone is constructive on ERNA-101 development, but the evidence mix still skews cautious because the most concrete near-term filings are about Nasdaq compliance and balance-sheet durability rather than operating proof points. Coverage is thin, no analyst target set was available, the packet carried no recent trusted-news flow, and the deterministic prior remained neutral with low catalyst density, so this remains a tentative monitoring memo rather than a confirmed bullish setup.

RankAlpha Sentiment Codex - 2026-05-01

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-05-03catalystReverse split execution and Nasdaq listing outcomeHigh impact

Ernexa disclosed a March 18, 2026 Nasdaq bid-price deficiency notice and said it would seek a hearing; the company also warned there is no assurance that a favorable Panel decision will be obtained or that its securities will remain listed on The Nasdaq Capital Market. The April 13, 2026 definitive information statement authorized a 1-for-10 to 1-for-25 reverse split, effective no earlier than 20 calendar days after mailing, to support regaining compliance. At ERNA's size, listing status and reverse-split execution remain the nearest stock-specific swing factors [#8-K-2026-03-20] [#DEF14C-2026-04-13].

2026-08-31eventRunway durability after February financingHigh impact

The 2025 10-K said Ernexa had about $1.9 million of cash at December 31, 2025, used about $7.0 million of operating cash in 2025, received about $9.6 million of net proceeds from the February 10, 2026 offering, and still concluded there was substantial doubt about its ability to continue as a going concern absent additional funding. That leaves capital access, dilution, or partnering as a core gating event before clinical entry [#10-K-2026-03-13].

2026-09-30catalystERNA-101 IND submission and first-in-human start windowHigh impact

Company communications said FDA pre-IND feedback provided a path toward IND submission and a first-in-human ovarian-cancer trial, with tech transfer already underway. Reaching IND clearance and opening the study would be the first material operating de-risking step for the platform, but this remains a preclinical milestone path rather than validated clinical evidence [#PR-2026-01-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-01 • Updated nightlySource: Internal modelMethodology